Biopharma deal-making has continued at a steady pace during the novel coronavirus pandemic – helped by frequent transactions related to COVID-19 – but the industry also is getting more used to the limitations imposed by social distancing, speakers said on panel at BIO’s digital meeting.
Biopharmas Manage To Deal During Pandemic
BIO 2020 Panel Suggests Driving Factors For Deal-Making Remain The Same
M&A activity faces numerous hurdles during the COVID-19 pandemic but companies are finding different ways to negotiate, conduct due diligence and get deals completed, BIO 2020 speakers said.
